Technical analysis of Ocugen, Inc. (OCGN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Price Performance
| 1 month | -26.28% |
| 3 months | -20.34% |
| Year-to-date | -26.83% |
| 1 year | -25.17% |
| 3 years | +146.95% |
| 5 years | -87.54% |
52-Week Range
| 52-week High | $2.73 |
| 52-week Low | $0.97 |
| Avg Volume (90d) | 6.6M |
Technical Indicators
| SMA 50 | $1.30 |
| SMA 200 | $1.51 |
| Beta | 2.81 |
| 30-day Volatility (annualised) | 81.7% |
| Price vs SMA 50 | -24.2% |
| Price vs SMA 200 | -34.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.56 | |
| 2025-11 | $1.24 | -20.5% |
| 2025-12 | $1.35 | +8.9% |
| 2026-01 | $1.45 | +7.4% |
| 2026-02 | $1.82 | +25.5% |
| 2026-03 | $1.81 | -0.5% |
| 2026-04 | $1.73 | -4.4% |
| 2026-05 | $1.38 | -20.2% |
| 2026-06 | $1.53 | +10.9% |
| 2026-07 | $1.23 | -19.6% |
| 2026-08 | $1.33 | +8.1% |
| 2026-09 | $0.99 | -25.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $0.06 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | $0.03 | $1M |
| 2026-09-14 | | |
| 2026-09-14 | $36.39 | $67M |
Price
| Price | $1.00 |
| Market Cap | $339M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -20.88 |
| EV / EBITDA | -6.40 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -5.31 |
| Current Ratio | 0.80 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -13.40 |